A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Lipid-Altering Efficacy and Safety and Tolerability of MK0524A [niacin/laropiprant] in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia.

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Lipid-Altering Efficacy and Safety and Tolerability of MK0524A [niacin/laropiprant] in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia.

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Oct 2014

At a glance

  • Drugs Niacin/laropiprant (Primary)
  • Indications Hypercholesterolaemia; Hyperlipidaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 15 Nov 2010 Trial location (China) identified as reported by ClinicalTrials.gov.
    • 05 May 2010 Merck Sharp and Dohme Corp Company added as trial affiliate, actual patient number added as 646 as reported by ClinicalTrials.gov.
    • 15 May 2009 Actual end date (1 Mar 2008) added as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top